Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Good news link.
[LINK REMOVED]
[LINK REMOVED]
theguardian.com/society/2023/jul/10/rsv-vaccine-respiratory-syncytial-virus-older-adults-approved-uk-medicines-regulator
Great news.
[LINK REMOVED]
Maybe 1200. But I've had GSK for over 5 years and seen this go between 1200 and 1800 like a yoyo. I've set a ridiculous target of 2000 to let me collect dividend income.
Looks like 1300 didn’t do it. Next stop 1200……
Dunno ...I think is a great defensive stock and given the times we live in, I rather hedge my bets here than US stocks for example, Inflation won't stay around forever, these are great times to fill your boots IMHO
TerryMC1 and RonnieH contribute doom and gloom on numerous BB's, 407 posts in the last 30 days between them. Check out their posting history, pathetic delusional traders.
It is precisely for times like these that I keep cash on standby. Chewise is right. This a buying opportunity and we should be grateful these come along from time to time. GSK, LGEN, NG, DGE and a whole bunch of other FTSE giants are well down right now and all pay divs and all will recover one day, but maybe not Vodafone, If you don't like it, check the amall print where it says you might not get your money back and put your monry in the post office instead.
Ive put a limit buy at 1200, my hunch tells me thats about right.... but what would I know ! :) gla
If you believe in this company, which you must do as you hold shares, why would you sell at £12 and not be buying?
I was under the impression that after last sale of Hln shares, there were to be no more sales by either party for 60 days, which is still a week away?
If you think this is bad try holding Vodafone...That will make your hair go curly....
It does seem to keep flopping!
Two weeks after the 5.5% gains from the latest Zantac news and we are back down to where we started. This share is a shambles. How much longer do we persevere with this circus of a leadership team??
Having held this stock for 6 years it's time to move on. Zero increase in the SP during that time yet the likes of AZN have increased by almost 100%
So it's decision time, when to sell and where to put it !!
A bid is our best hope, travesties. Do you know of anyone with .the necessary billions and the enthusiasm, though?
That is what I have been asked on here but sadly, I am not in that league; so we just stay put and take the divis!
You can understand why private investors are losing patience.
What would it take to move the stock up 10%?
Red again….. everyone else in the green. Has to be the worst valued stock in the ftse 100.
RSV: The director of the U.S. Centers for Disease Control and Prevention signed off on the use of new vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections in older adults.
Tony Wood, Chief Scientific Officer, GSK, said: “GSK’s successful development of an RSV vaccine to help protect older adults from RSV lower respiratory tract disease (LRTD) represents a major scientific advance, resulting from years of collaboration across academia, industry, and research centres. We are grateful to the ACIP and CDC for recognising the potential of Arexvy and look forward to partnering with public health officials, healthcare professionals and payers to make it available for eligible older adults in the US before this year’s RSV season begins.”
There are an estimated 55.8 million people aged 65 and older in the US1 who are at increased risk of RSV, a common, contagious virus that can lead to serious respiratory illness.2 RSV causes approximately 177,000 hospitalisations and an estimated 14,000 deaths in this age group in the US each year. For adults 60 and older, data suggest an increased risk for severe RSV infection that can lead to hospitalisation. Older adults, including those with underlying medical conditions*, such as chronic heart disease, chronic lung disease or diabetes, are at high risk of severe RSV illness and account for the majority of RSV hospitalisations.
You may miss the subtle point of the below
1. the reference to FDA is for US approvals which means the product can be sold in US
2. the figures point to the US which is relavent for the approval.
Once the approval is granted in EU, Asia market then the statement 'Those locations provide more sales.' is valid. Until the approval is granted within those regulatory markets there are 0 sales.....
Can we have some estimates for Europe, Asia and Africa.
Those locations provide more sales.
Gonorrhea is a very common infectious disease. CDC estimates that, annually, more than 700,000 people in the United States get new gonorrheal infections, and less than half of these infections are reported to CDC.
GSK's gonorrhoea vaccine receives FDA's 'fast-track' designation. June 27 (Reuters) - GSK's (GSK.L) vaccine candidate to treat sexually transmitted infection gonorrhoea has been granted a fast-track designation by the U.S. Food and Drug Administration (FDA).
Markets slowly chipping away at the increase from last week already despite all the good headlines. This share price never ceases to amaze me. Multiple approvals this week and it still ends in the red. Lost for words
When this grizzly bear market finally turns, This will shoot up to....£16 if we're lucky! I still hold on to the hope that we will get nearer £20 in a contested bid, 3
Best to NOT publish settlement amounts.
Avoid establishing 'benchmarks' as future settlements likely to be more expensive.